Trial Profile
Renal hemodynamic effects of aliskiren (rasilez) in comparison to ramipril (tritrace) in patients with overweight/obesity and hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2012
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Ramipril (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms renal-HEALTH-STudY
- 15 Oct 2010 New trial record